| Field | Specification |
|---|---|
| Alternative names | GP 47680 |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C15H12N2O2 |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Oxcarbazepine, also known as GP 47680, is a sodium channel blocker[1]. It significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines[2], exhibiting anti-cancer and anticonvulsant effects[2][3]. It is supplied as a white to light yellow solid (C15H12N2O2, MW 252.27) at 99.72% purity.
Physical & Chemical Properties
| CAS Number | 28721-07-5 |
|---|---|
| Molecular Formula | C15H12N2O2 |
| Molecular Weight | 252.27 g/mol |
| Purity | 99.72% |
| Appearance | Solid |
| Color | White to light yellow |
| SMILES | O=C(N1C2=CC=CC=C2CC(C3=CC=CC=C31)=O)N |
| Signaling Pathway | Membrane Transporter/Ion Channel; Apoptosis |
| Solubility | In Vitro: DMSO: 50 mg/mL (198.20 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 2 years; -20°C, 1 year. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 50 mg/mL (198.20 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 2 years) or -20°C (up to 1 year); avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 1.67 mg/mL (6.62 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 1.67 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (16.7 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Protocol 2
| Composition | 10% DMSO + 90% Corn Oil |
|---|---|
| Result | ≥ 1.67 mg/mL (6.62 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 1.67 mg/mL (saturation not determined). Use with caution if continuous dosing will exceed two weeks. For 1 mL of working solution: add 100 μL DMSO stock (16.7 mg/mL) to 900 μL corn oil. |
Data provided by the manufacturer.
In Vitro
Oxcarbazepine markedly suppresses glioblastoma cell growth, reaching IC50 at therapeutic concentrations. In U87 and T98 cell lines, the IC50s of Oxcarbazepine are 12.35 and 9.45 μg/mL, respectively[2].
Cell Viability Assay[2]
| Cell Line | Human glioma cell lines U-87 MG and T98G |
|---|---|
| Concentration | 2.5, 5, 10, 20, and 40 μg/mL |
| Incubation Time | 72 hours |
| Result | The growth inhibition for the T98G cell line for each concentration was 17.7±4.1% (2.5 μg/mL), 21.1±3.6% (5 μg/mL), 53.6±14.2% (10 μg/mL), 82.2±2.3% (20 μg/mL), and 85.0±2.3% (40 μg/mL). The growth inhibition for U-87 MG cell line for each concentration was −1.7±5.1% (0.008 μg/mL), 5.3±2.4% (0.08 μg/mL), 3.5±7.4% (0.8 μg/mL), 0.3±9.2% (16 μg/mL), and −4.2±9.6% (40 μg/mL). |
In Vivo
Oxcarbazepine protects mice and rats from generalized tonic-clonic seizures induced by electroshock, with ED50 values ranging from 13.5 to 20.5 mg/kg p.o. Rats treated daily with Oxcarbazepine for 4 weeks show no tolerance to this anticonvulsant effect.
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
In Vivo Chemical Screening in Zebrafish Embryos Identified FDA-Approved Drugs That Induce Differentiation of Acute Myeloid Leukemia Cells. Int J Mol Sci 2024 Jul 16;25(14):7798. PMID: 39063039
Enhancing local glioblastoma treatment via in vitro synergistic pairing of Janus kinase/signal transducer and activator of transcription-3 inhibitor with antiepileptic drugs. J Pharmacol Exp Ther 2025 Oct 31;393(1):103767. PMID: 41406909
